Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study.

Agnieszka DurbajłoMarcin ŚwieżyńskiBeata ZiembaDanuta Starzyczny-SłotaMarzena Samborska-PlewickaAnna Cencelewicz-LesikowAgata Chrzanowska-KapicaAneta Dobrzyńska-RutkowskaIwona Drab-MazurMonika Kulma-KreftMagdalena Sikora-SkrabakaElwira MatuszewskaMałgorzata Foszczyńska-KłodaTomasz LewandowskiGrzegorz SłomianKrystyna Ostrowska-CichockaEwa ChmielowskaRafał WiśniowskiAnna TwardoszKatarzyna WierzbickaLeszek RumianowskiLucjan Wyrwicz

Published in: Cancers (2024)

The benefits/risks of Aflibercept plus FOLFIRI administered per the Polish reimbursement criteria in second-line treatment of mCRC after failure of a prior oxaliplatin-based regimen is confirmed.

Keyphrases

metastatic colorectal cancer
randomized controlled trial
age related macular degeneration
systematic review
human health
combination therapy
risk assessment
replacement therapy